glp 1 used for weight loss The FDA has approved the first GLP-1 pill loss, a milestone in the growth of the revolutionary drugs. The drug, a once-a-day Wegovy tablet, is also approved for reducing cardiovascular GLP-1 Agonists - What is

10 / 2026 Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people living with obesity or overweight in Phase 3 trial In SYNCHRONIZE-1, participants lost up to an average of 39.2 lb (17.8 kg) from baseline after 76 weeks of treatment with survodutide, a glucagon/GLP-1 receptor dual agonist1 The trial met both weight loss primary endpoints and its key secondary endpoint evaluating waist circumference, a predictor of cardiometabolic risk, together demonstrating survodutide's potential to broadly improve metabolic health1 In addition to these positive results, Boehringer is advancing its broad metabolic health R&D program, exploring multiple pharmaceutical approaches to weight management including oral treatments

Before writing a prescription, a clinician should review your full medical history and current medications

5 and 6

Consistency matters more than dose take it daily rather than sporadically

Glickman speaks with The Wellnest at HUM media about GLP-1 plateaus and how to navigate them